Bachem and Debio conclude long-term supply agreement for triptorelin pamoate. Bachem AG today announced the conclusion of a long-term agreement with Debio, a Swiss drug development company, for the supply of triptorelin pamoate. Unter the terms of this agreement, Bachem will supply Debio with the active substance for its product Decapeptyl® (Trelstar® in the USA). Triptorelin pamoate is a peptidic active pharmaceutical ingredient (API), which is used for treating prostate cancer, endometriosis and premature puberty.

Press release